The 6 analysts offering 12-month price forecasts for Verona Pharma PLC have a median target of 16.07, with a high estimate of 50.00 and a low estimate of 5.17. The median estimate represents a +281.67% increase from the last price of 4.21.
The current consensus among 6 polled investment analysts is to Buy stock in Verona Pharma PLC. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.71
Reporting Date Aug 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.